Inflammatix, Inc. — Form D
Inflammatix, Inc. of BURLINGAME, CA, a company, filed a Form D exempt-offering notice with the SEC on 2020-02-03. The offering totals $32.1M, of which $32.1M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2020-02-03
- Form: D
- Accession: 0001801477-20-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $32.1M
- Amount sold: $32.1M
- Investors: 6
- Date of first sale: 2020-01-09
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-359633
Issuer
- Name: Inflammatix, Inc.
- CIK: 0001801477
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2016
- Address: 863 MITTEN ROAD, SUITE 104, BURLINGAME, CA, 94010
- Phone: 650-443-3030
Officers, directors & promoters (8)
| Name | Role | Location |
|---|
| JONATHAN ROMANOWSKY | Executive Officer | BURLINGAME, CA |
| Michael Rubin | Director | Richmond Hill, A6 |
| Justin Kao | Director | Baltimore, MD |
| KENNETH BAHK | Director | BURLINGAME, CA |
| TIMOTHY SWEENEY | Director | BURLINGAME, CA |
| TIMOTHY SWEENEY | Executive Officer | BURLINGAME, CA |
| STEVEN TABLAK | Director | BURLINGAME, CA |
| DAVID PERSING | Director | BURLINGAME, CA |
Other filings by this issuer (1)
More